L-Proline
|
Basic information |
| Metabolite name | L-Proline |
 | HMDB0000162 |
 |
C00148 |
 |
145742 |
| Synonyms | Proline |
| No. of studies | 75 |
|
Basic information |
| Metabolite name | L-Proline |
| HMDB0000162 |
|
C00148 |
|
145742 |
| Synonyms | Proline |
| No. of studies | 75 |
|
Relationship between L-Proline and depression (count: 75) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M012 | Type1 | CVS group vs. control group | Urine | Wistar rat | Down |
| Study M012 | Type2 | CVS + CSGS group vs. CVS group | Urine | Wistar rat | Up |
| Study M012 | Type2 | CVS + fluoxetine group vs. CVS group | Urine | Wistar rat | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M020 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M030 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M062 | Type1 | CUMS group vs. control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M072 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M072 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M074 | Type1 | sCSDS group vs. control group | Faece | C57BL/6JJmsSlc mouse | Down |
| Study M075 | Type1 | post stroke depressed group vs. post stroke non-depressed group | Plasma | Human | Up |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1020 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1020 | Type1 | CUMS group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M1020 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + low dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1103 | Type1 | SLE with depression group vs. control group | Faece | Human | Up |
| Study M1129 | Type1 | high dose of perfluorooctane sulfonate group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M119 | Type1 | LH group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M132 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M137 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M463 | Type3 | DG group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M472 | Type3 | S-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | R-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
| Study M516 | Type1 | SMG-treated group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M553 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M553 | Type2 | CUMS + venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M630 | Type2 | acupuncture + antidepressant group, post vs. before treatment | Urine | Human | Up |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M636 | Type2 | CUMS + Shugan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M636 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Down |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M672 | Type2 | SMG + Hemerocallis citrina extracts group vs. SMG group | Urine | Sprague-Dawley rat | Down |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Down |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
| Study M741 | Type2 | MDD group, post vs. before SSRI treatment | Plasma | Human | Up |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M790 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M790 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M791 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Cecum | Sprague-Dawley rat | Up |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M867 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M890 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M896 | Type1 | eating disorders with MDD group vs. eating disorders without MDD group | Plasma | Human | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M924 | Type2 | CUMS + aerobic exercise group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M943 | Type1 | CUMS group vs. control group | Liver | ICR mouse | Up |
| Study M955 | Type2 | CUMS + tryptophan-enriched whey protein-based group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |